IN8bio, Inc.

NASDAQ: INAB · Healthcare · Biotechnology

PublicHQ New York City, NY · New YorkCIK 0001740279Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 52DQ —GM —SS 34

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, filing timeliness · ↓ listing tenure, workforce scale

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$19.4M

Employees

as of 2026-08-22

Market cap

$12.3M

as of 2026-08-22

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$19.4M-$19.4M2025

Operating income-$19.4M-$19.4M2025

Total assets$32.3M$32.3M2025

Liabilities$4.7M$4.7M2025

Equity$27.6M$27.6M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is IN8bio, Inc.’s financial profile?

IN8bio, Inc. earned -$19.4M in FY2025 net income.

Peers · Healthcare

Passage Bio, Inc.——Anebulo Pharmaceuticals, Inc.——Intensity Therapeutics, Inc.——Brainstorm Cell Therapeutics Inc.——Jasper Therapeutics, Inc.——PDS Biotechnology Corporation——

Neighbors

New York →

JPMorgan Chase & Co.$182.4B72B Morgan Stanley$34.3B61C The Goldman Sachs Group, Inc.——Philip Morris International Inc.$40.6B86A American Express Company$41.3B78B+Citigroup Inc.$85.2B55C

Key facts

CEOWilliam T.

SectorHealthcare

IndustryBiotechnology

HeadquartersNew York City, NY

ExchangeNASDAQ: INAB

Employees18

IPO date2021-07-30

Latest filings

10-Q2026-08-06 8-K2026-08-06 8-K2026-06-01 8-K2026-05-07 10-Q2026-05-07 DEF 14A2026-03-26 8-K2026-03-12 10-K2026-03-12

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.